Krakowiak Maxwell sold $236K of RVTY

JP Morgan kept its Neutral rating on Revvity but raised its price target to $160 from $155, citing a 3.2% increase. The new target suggests a 2.1% downside from the Nov 3 close of $163.48. Recent analyst notes on Revvity have price targets ranging from $172 to $185.

Revvity reported Q3 earnings, highlighting AI-driven demand growth in high-content screening instruments, with revenue up 4% and backlog expansion across categories. Diagnostics revenue reached $330M, with mid-single-digit growth. The company raised its 2026 organic growth outlook to 5% and expects Q4 revenue of ~$755M. Margins improved, and free cash flow was strong. Revvity plans to discuss its AI strategy and outlook at an Investor Day event.

Revvity Inc (RVTY) reported Q3 2026 earnings, highlighting 7% organic growth but guiding Q4 growth down to 5% due to lower reagent and software growth. APAC saw a low single-digit decline, and China's immunodiagnostics business remains a margin headwind. Software growth is expected to moderate, and AI demand is emerging but not yet quantified. The company confirmed sustainable incremental margins in the low 40s and expects a durable pharma biotech recovery.

Revvity (RVTY) reported Q3 2026 earnings, highlighting AI-driven demand growth across its portfolio, including high-content screening, life sciences reagents, and detection instruments. The company expects 5% full-year organic growth and adjusted EPS of $5.40-$5.45, up from initial forecasts. Revvity also launched new AI-native offerings in its signals software business and a new diagnostic kit for early type 1 diabetes detection in Europe.

Revvity, Inc. reported Q3 2026 earnings, highlighting a 9% organic growth in Life Sciences, driven by reagent and software demand. Management raised full-year guidance to 5% growth, citing AI-related demand and operational efficiencies. The company expects sustainable margins and plans to divest its China immunodiagnostics business in 2027. Key growth areas include reagents and Signals software, with AI-native offerings launching in 2026.

Revvity (RVTY) shares rose 11% after the company raised its 2026 revenue and profit outlook and reported better-than-expected Q3 results. The life sciences tools and diagnostics firm updated its non-GAAP EPS guidance.